Log in
医药行业创新药专题2022医保国谈梳理：医保谈判日趋成熟，关注商业化平台型创新药企-20230106-华安证券-31页
English body is not available for this report yet; showing the Chinese version. View in Chinese
常见问题
- 这份报告主要研究什么？
- 《医药行业创新药专题2022医保国谈梳理：医保谈判日趋成熟，关注商业化平…》主要讨论：医保谈判日趋成熟，关注商业化平台型创新药企 核心观点： 2022政策口创新药规范及利好频出，制造端鼓励创新、诊疗端细化规范、支付端开源节流。 2023展望疫后复苏及用药升级，二季度后院内秩序…
- 报告来自哪个机构？何时发布？
- 来源机构：华安证券，报告发布于 2023-01-06，篇幅约 33 页。
Copyright notice
This report is aggregated from publicly available internet sources. Copyright belongs to the original authors or rights holders. If you are a rights holder and believe content on this platform infringes your rights, please email copyright@ruishubaogao.com . We will remove the content promptly after verification.